Shelley Gandhi Joins Firm – Headlines ELIQUENT’s Expanded Pharmacovigilance Service Offerings
4.11.2024 21:50:00 EET | Business Wire | Press release
ELIQUENT Life Sciences (ELIQUENT), a global regulatory consulting firm, today announced that internationally recognized pharmacovigilance (PV) expert Shelley Gandhi has joined the firm. This strategic addition to ELIQUENT’s robust team of regulatory and quality leaders reinforces the firm’s commitment to delivering integrated solutions that streamline compliance, manage risk, and accelerate time-to-market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241104361511/en/
Shelley Gandhi joins ELIQUENT Life Sciences - bolsters expanded Pharmacovigilance & Risk Management Solutions (Photo: Business Wire)
“Shelley’s firsthand knowledge of regulatory expectations and her proficiency in navigating complex regulatory challenges will be instrumental in expanding ELIQUENT’s pharmacovigilance solutions to meet the growing global demand for comprehensive safety and risk management across diverse markets,” said Tim Dietlin, Chief Executive Officer, ELIQUENT Life Sciences.
Global Pharmacovigilance Expertise
Shelley Gandhi brings more than three decades of global PV and risk management experience to her role at ELIQUENT. Her extensive professional background includes more than 19 years of service at the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). During her tenure, Shelley served in multiple senior positions where she gained extensive knowledge of all European regulatory processes relating to monitoring the safety of licensed medicinal products and ancillary devices.
Shelley’s distinguished MHRA career included a role as the UK representative on the European Medicines Agency’s (EMA) EudraVigilance Expert Working Group. In this capacity, Shelley was instrumental in shaping EMA’s system for managing and analyzing information on suspected adverse reactions to medicines. Her contributions further enhanced key PV processes and systems across Europe.
Prior to joining ELIQUENT, Shelley served for more than 12 years as a strategic PV advisor to clients building and managing risk management systems. Shelley provided support to biotechnology clients across a broad range of therapeutic areas. Her experience includes strategic and technical advisory services in multiple markets from early clinical development to launch readiness.
At ELIQUENT, Shelley works with clients to ensure compliance with global safety standards, while anticipating changes, and preparing proactive solutions. Her deep understanding of drug safety and risk management protocols, coupled with her regulatory and industry experiences, amplifies ELIQUENT’s expanded PV and Risk Management Solutions. Learn more about Shelley.
Pharmacovigilance & Post-Market Surveillance Solutions
ELIQUENT’s expanded PV and Risk Management Solutions optimize practices to ensure consistency, compliance and operational efficiency across diverse markets. With decades of experience developed as leaders in both the public and private sectors, ELIQUENT’s industry-recognized PV experts support innovators with precision and expertise - enabling clients to confidently navigate global post-marketing surveillance, adverse event reporting, and risk management planning. Because there is no one-size-fits-all approach, each solution is built to support regulatory objectives, while aligning with evolving global demands. ELIQUENT’s customized global Pharmacovigilance & Risk Management Solutions include:
- Global Support: Trusted guidance when navigating and complying with global PV regulations
- Adverse Event Reporting: Systematic identification, objective analysis, and strategic guidance responding to unintended occurrences
- Regulatory Reporting: Technical skill and institutional knowledge of complex regulatory reporting obligations
- Signal Detection: Expert development and implementation of detection processes, including reporting and risk communication
- Risk Assessment & Management: Proactive identification, assessment and planning to manage potential risk and ensure regulatory compliance
- Post-Marketing Surveillance: Established network experts to support commercial product safety systems and reporting function
- Risk Communications: Strategic development of communications plans to address emerging safety concerns and instill confidence in the market
- Clinical Trials Safety Oversight: On-demand resources to support safety monitoring before and after regulatory approval
- Qualified Person for Pharmacovigilance (QPPV): Comprehensive QPPV solutions ensure clients meet EU, UK, and regional pharmacovigilance requirements, while safeguarding patient safety.
- Global PV Training: Bespoke pharmacovigilance training programs to uphold the highest regulatory standards across diverse global markets.
Integrated Solutions – Full-Service Support
ELIQUENT redefines regulatory consulting with a full-service platform that delivers integrated solutions across the product lifecycle. The firm's unprecedented assembly of regulatory leaders, industry experts, and technical specialists collaborate seamlessly to advise clients on the complex process of bringing new therapies to market and manufacturing them to quality standards. ELIQUENT's integrated platform of regulatory solutions feature the following integrated service offerings:
- Regulatory Affairs Solutions: From the earliest phases of innovation through regulatory submissions, to post- approval support, ELIQUENT guides companies to approval and beyond.
- Pharmacovigilance & Risk Management Solutions: With an approach that includes both strategic direction and hands-on global support, customized PV solutions empower companies to operate with confidence.
- Quality & Compliance Solutions: Highly specialized compliance experts build customized solutions that equip companies with best- in-class strategic support, technical expertise, and project-based solutions.
- Remediations Solutions: Respected professionals and global experts bring an unmatched level of credibility and trust when interacting with regulators and guiding companies to remediation solutions.
- Talent Solutions: Whether you need a team of one or 100+, ELIQUENT’s talent solutions gives clients the ability to rapidly scale teams to the right size, with the right level of expertise, in the right locations.
About ELIQUENT Life Sciences
ELIQUENT Life Sciences is the fusion of six global regulatory consultancies: Validant, Greenleaf Health, DataRevive, Oriel Stat-a-Matrix, RApport Global, and IDEC. ELIQUENT team works cross-functionally to deliver the global solutions that pharmaceutical, biotechnology, and medical device companies need to gain and maintain authorization for the products. ELIQUENT’s comprehensive services support innovators across therapeutic modalities, phase-based pathways, and major global markets. ELIQUENT’s continued growth is supported by GHO Capital, the European specialist investor in healthcare.
Learn more about ELIQUENT Life Sciences at eliquent.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241104361511/en/
Contacts
Taryn Fritz Walpole
twalpole@eliquent.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
White Paper Examines Early Clinical Development of B-Cell Depletion Therapies in Autoimmune Disease30.7.2026 14:01:00 EEST | Press release
Novotech, a leading global full-service clinical research organization (CRO) and scientific advisory company, has released a new white paper, B-Cell Depletion in Autoimmune Disease: Considerations for Early Clinical Development, providing practical guidance on the scientific, clinical, and operational factors shaping the development of emerging B-cell depletion therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730139661/en/ B-cell depletion has become an important area of research in autoimmune disease as developers investigate whether deeper and more sustained depletion may support longer periods of remission and potentially influence immune system recovery. Emerging approaches, including in vivo CAR-T therapies and T-cell engagers, are expanding the range of development strategies available beyond established B-cell-targeting treatments. The white paper looks at the early development decisions sponsors face as t
Industrial Info Resources Launches IIR Envoy ™ MCP, Bringing Human-Verified Industrial Intelligence Directly Into AI Through Model Context Protocol30.7.2026 14:00:00 EEST | Press release
Industrial Info Resources (IIR), a leading provider of energy and industrial market intelligence built on primary research and human verification, today announced the launch of IIR Envoy MCP; this new Model Context Protocol connection plugs IIR's authoritative industrial database directly into the AI platforms professionals already use. As an example, with IIR Envoy MCP, an analyst can ask, "What refinery capacity is offline in Europe since this morning's weather event?" or "Which power plants near Houston have upcoming outages?" and receive an instant, source-cited answer drawn from IIR's live data. As AI becomes increasingly embedded in decision-making tools, the quality of AI-generated insights depends entirely on the quality of the underlying data. IIR Envoy MCP was built on that principle. "The information age was about collecting data. The knowledge age was about understanding it. Today, technology has brought us to the Answer Age. It’s not a question of if someone can get an ans
120 Million AI Pay Transactions in a Single Week: AI Shopping Agents Move From Theory to Checkout30.7.2026 13:45:00 EEST | Press release
The debate is shifting as early examples show AI shopping agents completing transactions in some markets. According to NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, its global report The Commerce Revolution: Where East Meets West points to agentic commerce moving from experiment toward everyday infrastructure. According to Ant Group, Alipay AI Pay processed more than 120 million transactions during the week of February 5–11, 2026, while Adobe Analytics reported that traffic from generative AI sources to US retail websites increased by 1,200% between July 2024 and February 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730837106/en/ Agentic commerce is beginning to move from forecast to real-world use in some markets. In China, AI agents are already completing purchases at meaningful scale, and analysts now put the global opportunity at $3–5 trillion by 2030. This is the second release in NielsenIQ’
Quectel Launches FCE870X and FME170X Tri-band Wi-Fi 7 Modules With Bluetooth 6.0 for Set-top Boxes, Gaming Devices and More30.7.2026 11:00:00 EEST | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the FCE870X and FME170X tri-band Wi-Fi 7 modules, powered by the Synaptics SYN4384 chipset and designed for set-top boxes, gaming devices, digital signage, VR/AR headsets, smart gateways and other high-performance connected products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730986067/en/ Quectel launches FCE870X and FME170X tri-band Wi-Fi 7 modules with Bluetooth 6.0 for set-top boxes, gaming devices and more The FCE870X and FME170X share the same high-end feature set and differ only in form factor. The FCE870X Wi-Fi 7 module uses a Compact LCC package for embedded designs, while the FME170X Wi-Fi 7 module uses a Compact M.2 package for modular, slot-based systems. Device makers can choose the option that best fits their platform without compromising wireless performance. “These high-end Wi-Fi 7 modules are engineered to run acro
Singapore Selects Thales for Next-generation AI-powered Air Traffic Management System Serving One of Asia’s Busiest Airspaces30.7.2026 11:00:00 EEST | Press release
The Civil Aviation Authority of Singapore (CAAS) has awarded Thales a landmark contract to develop a new NexGen Air Traffic Management System (ATMS) and air traffic control radars, marking a major step towards a more efficient, safer and more sustainable aviation ecosystem. The NexGen ATMS will replace the current LORADS III system with Thales’ TopSky – ATC One solution. The project also covers knowledge transfer including through having CAAS officers join the project office in France and other localisation projects in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730033092/en/ (c) Thales A next-generation system to support the growth of regional air traffic As Singapore prepares to meet rising demand for air travel, the NexGen ATMS will play a pivotal role in introducing a fully integrated, AI-enabled air traffic control environment. At the heart of the system is TopSky – ATC One, Thales’ next-generation auto
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom